An Open-Label, Randomized, 3-Treatment, 3-Period, 6-Sequence, Balanced Crossover Study to Characterize the Relative Bioavailability of Miricorilant Administered as 50-mg and 100-mg Kinetisol Tablets vs the 50-mg Spray Dried Dispersion Tablet Formulation With an Optional Food Effect Assessment in Healthy Adult Subjects
Latest Information Update: 02 Dec 2025
At a glance
- Drugs Miricorilant (Primary)
- Indications Alcoholism; Non-alcoholic steatohepatitis; Weight gain
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
Most Recent Events
- 02 Dec 2025 New trial record